| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 6, Issue 9 1185-1191, Copyright © 1995 by American Association of Cancer Research
ARTICLES |
GH Xiao, F Jin and RS Yeung
Division of Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Tuberous sclerosis 2 (Tsc2) gene is the target of a germline insertion in the Eker rat model of inherited cancer susceptibility. This tumor suppressor gene, when mutated, gives rise to a spectrum of epithelial and nonepithelial neoplasms in the rat, as well as multisystem involvement of hamartomas in the human. In this study, we characterized the rat Tsc2 cDNA and found that it is highly homologous with the human gene, including a conserved rap1GAP catalytic domain. Sequence analysis of independent rat clones from a kidney cDNA library revealed distinct but related variants of the Tsc2 transcripts stemming from alternative splicing involving two noncontiguous exons within the translated region. The first of these, located at amino acids 947 to 990, gives rise to isoforms with or without the 129-bp exon. There exists another variant related to the use of a "cryptic" splice acceptor site in the downstream exon that results in an in-frame 3-bp deletion. A separate 69-bp exon encoding a novel serine-rich amino acid sequence (1272 to 1295) was also alternatively spliced. Together, we have found a minimum of four and potentially eight Tsc2 isoforms that are differentially expressed in a tissue-specific manner. These splice variants are highly conserved in the human gene, suggesting a possible functional role of these Tsc2 isoforms in various cell regulatory and developmental processes.
This article has been cited by other articles:
![]() |
K Mayer, M Goedbloed, K van Zijl, M Nellist, and H-D Rott Characterisation of a novel TSC2 missense mutation in the GAP related domain associated with minimal clinical manifestations of tuberous sclerosis J. Med. Genet., May 1, 2004; 41(5): e64 - e64. [Full Text] [PDF] |
||||
![]() |
T. Kobayashi, H. Mitani, R.-i. Takahashi, M. Hirabayashi, M. Ueda, H. Tamura, and O. Hino Transgenic rescue from embryonic lethality and renal carcinogenesis in the Eker rat model by introduction of a wild-type Tsc2 gene PNAS, April 15, 1997; 94(8): 3990 - 3993. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-H. Xiao, F. Shoarinejad, F. Jin, E. A. Golemis, and R. S. Yeung The Tuberous Sclerosis 2Gene Product, Tuberin, Functions as a Rab5 GTPase Activating Protein (GAP) in Modulating Endocytosis J. Biol. Chem., March 7, 1997; 272(10): 6097 - 6100. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |